Potential applications of matrix metalloproteinase inhibitors in geriatric practice

Israel Medical Association Journal

Volumn 5, Issue 5, 2003, Pages 361-364

  Marder, Galina S ^a   Greenwald, Robert A ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Aortic abdominal aneurysm; Degenerative processes; Extracellular matrix; Macular degeneration; Matrix metalloproteinases; Osteoarthritis

Indexed keywords

CELLS; DISEASES; GERIATRICS; PHYSIOLOGY; TISSUE;

NEOPLASTIC PROCESSES;

ENZYME INHIBITION;

AGGRECANASE; BATIMASTAT; CIPEMASTAT; COLLAGENASE 3; CORTICOSTEROID; DOXYCYCLINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; HEPARIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL COLLAGENASE; PLATELET DERIVED GROWTH FACTOR; RETINOID; RO 130830; RO 32 35555; STROMELYSIN; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA ANEURYSM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GERIATRICS; HUMAN; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN EXPRESSION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TISSUE REGENERATION; TISSUE REPAIR; WOUND HEALING;

AGED; AORTIC ANEURYSM; GERIATRICS; HUMANS; MACULAR DEGENERATION; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 0037645957     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem 1995;376:345-55.
2. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases. Arthritis Rheum 2002;46(1):13-20.
3. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77(5):863-8.
4. Saito S, Zempo N, Yamashita A, Takenaka H, Fujioka K, Esato K. Matrix metalloproteinase expression in atherosclerotic aneurysmal disease. Vasc Surg 2002;36(1):1-7.
5. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-60.
6. Zempo N, Kouama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Atheroscler Thromb Vasc Biol 1996;16(1):28-33.
7. Drummond AH. Metalloproteinases, cytokines and angiogenesis. Ann Rheum Dis 1995;54(9):765.
8. De Smet BJGL, De Kleijn D, Hanemaaijer R, et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: A study in the atherosclerotic Yucatan micropig. Circulation 2000;101(25):2962-7.
9. McMillian WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29(1):122-9.
10. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aneurysms. J Vasc Surg 2000;31(2):325-42.
11. Kenagy RD, Nikkari TS, Welgus HG, Clowes AW. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kd gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994;93(50):1987-93.
12. Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y. Significant increases in sera and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002;46(10):2625-31.
13. Elliott S, Cawston T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging 2001;18(2):87-99.
14. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001;60(11)(Suppl 3):62-7.
15. Brewster M, Lewis EJ, Wilson KL, et al. Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998;41(9):1639-44.
16. Leu ST, Batni S, Radeke MJ, Johnson LV, Anderson DH, Clegg DO. Drusen are cold spots for proteolysis: Expression of matrix metalloproteinases and their tissue inhibitor proteins in age-related macular degeneration. Exp Eye Res 2002;74:141-54.
17. Qi JH, Ebrahem Q, Yeow K, Edwards DR, Fox PL, Anand-Apte B. Expression of Sorby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinases inhibition and may promote angiogenesis. J Biol Chem 2002;277(16):13394-400.
18. Kvanta A, Shen WY, Sarman S, Sergard S, Steen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res 2000;21(3):684-90.
19. Hangai M, Kitaya N, Xu J, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161(4):1429-37.